IN8bio (NASDAQ:INAB) Releases Earnings Results, Beats Estimates By $0.03 EPS

IN8bio (NASDAQ:INAB) issued its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports.

IN8bio Trading Down 9.0 %

Shares of IN8bio stock traded down $0.02 on Thursday, hitting $0.23. 1,818,877 shares of the company’s stock traded hands, compared to its average volume of 6,671,047. The company has a fifty day moving average of $0.28 and a two-hundred day moving average of $0.30. IN8bio has a one year low of $0.22 and a one year high of $1.74. The company has a market capitalization of $18.39 million, a price-to-earnings ratio of -0.30 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of IN8bio in a report on Wednesday, February 12th.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.